Compare Glenmark Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA JUBILANT LIFE SCIENCES GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 11.9 15.2 78.6% View Chart
P/BV x 1.7 1.8 96.3% View Chart
Dividend Yield % 0.6 0.8 67.5%  

Financials

 GLENMARK PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
GLENMARK PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs712898 79.2%   
Low Rs484618 78.3%   
Sales per share (Unadj.) Rs349.6572.0 61.1%  
Earnings per share (Unadj.) Rs32.836.2 90.5%  
Cash flow per share (Unadj.) Rs44.359.5 74.5%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.30.6 56.4%  
Book value per share (Unadj.) Rs198.6301.9 65.8%  
Shares outstanding (eoy) m282.17159.28 177.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.71.3 129.0%   
Avg P/E ratio x18.220.9 87.2%  
P/CF ratio (eoy) x13.512.7 105.9%  
Price / Book Value ratio x3.02.5 119.9%  
Dividend payout %6.112.4 49.1%   
Avg Mkt Cap Rs m168,625120,694 139.7%   
No. of employees `00012.02.4 503.6%   
Total wages/salary Rs m20,56119,260 106.8%   
Avg. sales/employee Rs Th8,196.038,120.6 21.5%   
Avg. wages/employee Rs Th1,708.18,058.4 21.2%   
Avg. net profit/employee Rs Th768.52,414.3 31.8%   
INCOME DATA
Net Sales Rs m98,65591,108 108.3%  
Other income Rs m2,081357 582.4%   
Total revenues Rs m100,73691,466 110.1%   
Gross profit Rs m15,85817,390 91.2%  
Depreciation Rs m3,2593,709 87.9%   
Interest Rs m3,3462,198 152.2%   
Profit before tax Rs m11,33511,840 95.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-2,802 -59.7%   
Tax Rs m3,7563,268 114.9%   
Profit after tax Rs m9,2505,770 160.3%  
Gross profit margin %16.119.1 84.2%  
Effective tax rate %33.127.6 120.1%   
Net profit margin %9.46.3 148.0%  
BALANCE SHEET DATA
Current assets Rs m66,96845,848 146.1%   
Current liabilities Rs m40,21120,897 192.4%   
Net working cap to sales %27.127.4 99.0%  
Current ratio x1.72.2 75.9%  
Inventory Days Days8357 146.7%  
Debtors Days Days8151 159.4%  
Net fixed assets Rs m33,32265,498 50.9%   
Share capital Rs m282159 177.2%   
"Free" reserves Rs m55,77047,930 116.4%   
Net worth Rs m56,05248,089 116.6%   
Long term debt Rs m35,73842,429 84.2%   
Total assets Rs m132,888114,685 115.9%  
Interest coverage x4.46.4 68.7%   
Debt to equity ratio x0.60.9 72.3%  
Sales to assets ratio x0.70.8 93.5%   
Return on assets %9.56.9 136.4%  
Return on equity %16.512.0 137.5%  
Return on capital %17.812.4 143.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99812,422 507.2%   
Fx outflow Rs m22,85917,227 132.7%   
Net fx Rs m40,140-4,805 -835.4%   
CASH FLOW
From Operations Rs m13,24211,215 118.1%  
From Investments Rs m-6,990-10,118 69.1%  
From Financial Activity Rs m-7,3876,574 -112.4%  
Net Cashflow Rs m-2,9717,612 -39.0%  

Share Holding

Indian Promoters % 48.3 45.6 105.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 6.9 8.7 79.3%  
FIIs % 34.4 21.2 162.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.1 49.8%  
Shareholders   56,727 23,815 238.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS